# ICMJE DISCLOSURE FORM

Date: October 22 2021

Your Name: Claudia Verderio

Manuscript Title: Differential impact of inflammasome-induced EVs on immune cells: key control by the functional state of the recipient cell

Manuscript number (if known): ExRNA-21-17

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)                       | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution)                                     |
|---|--|--|---|
|   |  | Time frame: Since the initia   | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | None   |   |
|   |  |  |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | Horizon 2020 PREMSTEM<br>Project from Italian<br>Ministry of Health 2018<br>Italian Foundation for<br>Multiple Sclerosis, call | Research grant, partners, coordinator Pierre Gressens<br>Research grant, partner, coordinator R Ghidoni<br>Research grant, PI |
|   |  | 2018   |   |
| 3 | Royalties or licenses  | None   |   |
| 4 | Consulting fees  |  |   |
|   |  | FISM   | Member of the Scientific Advisory Board   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | None |  |
|----|--|------|--|
| 6  | Payment for expert testimony   | None |  |
| 7  | Support for attending meetings and/or travel   | None |  |
| 8  | Patents planned, issued or pending   | None |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | None |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | None |  |
| 11 | Stock or stock options   | None |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | None |  |
| 13 | Other financial or non-<br>financial interests   | None |  |

# Please summarize the above conflict of interest in the following box:

I was awarded research grants by the Organizations reported above, and was paid consulting fees to provide my expert opinion to the Scientific Committee of the Italian foundation for Multiple Sclerosis.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

#### ICMJE DISCLOSURE FORM

Date: October 22 2021 Your Name: Marta Lombardi Manuscript Title: Differential impact of inflammasome-induced EVs on immune cells: key control by the functional state of the recipient cell Manuscript number (if known): ExRNA-21-17

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |  |
|---|---|--|---|--|
|   | Time frame: Since the initial planning of the work        |  |   |  |
| 1 | All support for the present                               | None   |   |  |
|   | manuscript (e.g., funding,                                |  |   |  |
|   | provision of study materials,                             |  |   |  |
|   | medical writing, article                                  |  |   |  |
|   | processing charges, etc.)<br>No time limit for this item. |  |   |  |
|   | No time innit for this item.                              |  |   |  |
|   |   |  |   |  |
|   |   |  |   |  |
|   |   | Time frame: past   | 36 months   |  |
| 2 | Grants or contracts from                                  | None   |   |  |
|   | any entity (if not indicated                              |  |   |  |
|   | in item #1 above).  |  |   |  |
| 3 | Royalties or licenses                                     | None   |   |  |
|   |   |  |   |  |
|   |   |  |   |  |
| 4 | Consulting fees   | None   |   |  |
|   |   |  |   |  |

| 5        | Payment or honoraria for        | None |  |
|----------|---------------------------------|------|--|
|          | lectures, presentations,        |      |  |
|          | speakers bureaus,               |      |  |
|          | manuscript writing or           |      |  |
| G        | educational events              | Nana |  |
| 6        | Payment for expert<br>testimony | None |  |
|          | testimony                       |      |  |
| 7        | Support for attending           | None |  |
| <i>'</i> | meetings and/or travel          |      |  |
|          |                                 |      |  |
|          |                                 |      |  |
|          |                                 |      |  |
| 8        | Patents planned, issued or      | None |  |
| 0        | pending                         |      |  |
|          | penang                          |      |  |
| 9        | Participation on a Data         | None |  |
|          | Safety Monitoring Board or      |      |  |
|          | Advisory Board                  |      |  |
| 10       | Leadership or fiduciary role    | None |  |
|          | in other board, society,        |      |  |
|          | committee or advocacy           |      |  |
|          | group, paid or unpaid           |      |  |
| 11       | Stock or stock options          | None |  |
|          |                                 |      |  |
| 12       | Receipt of equipment,           | None |  |
| 12       | materials, drugs, medical       |      |  |
|          | writing, gifts or other         |      |  |
|          | services                        |      |  |
| 13       | Other financial or non-         | None |  |
|          | financial interests             |      |  |
|          |                                 |      |  |

# Please summarize the above conflict of interest in the following box:

No conflict of interest

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

# ICMJE DISCLOSURE FORM

Date: October 22 2021 Your Name: Francesco Di Virgilio Manuscript Title: Differential impact of inflammasome-induced EVs on immune cells: key control by the functional state of the recipient cell Manuscript number (if known): ExRNA-21-17

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|--|---|
|   |  | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | None   |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | Italian Association for<br>Cancer research   | Research grant, PI.   |
|   |  | Project of National<br>Interest (PRIN), Ministry of<br>Scientific Research                               | Research grant, PI  |
|   |  | CureAlzheimer USA  | Research grant, PI  |
| 3 | Royalties or licenses  | None   |   |
| 4 | Consulting fees  | Axxam spa (Italy)  | Consultant  |

|    |  | Biosceptre Ltd (UK) | Member of the Scientific Advisory Board |
|----|--|---------------------|---|
|    |  | La Caixa (Spain)    | Consultant                              |
| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | None                |   |
| 6  | Payment for expert testimony   | None                |   |
| 7  | Support for attending meetings and/or travel   | None                |   |
| 8  | Patents planned, issued or pending   | None                |   |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board  | None                |   |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid               | None                |   |
| 11 | Stock or stock options   | None                |   |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                                | None                |   |
| 13 | Other financial or non-<br>financial interests   | None                |   |

# Please summarize the above conflict of interest in the following box:

I was awarded research grants by the Organizations reported above, and was paid consulting fees to provide my expert opinion on a number of issues related to P2X7R and inflammasome biology.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.